Varun Mehra

Super important piece for GVHD community.

Time to step up and diligently apply regulatory framework for emerging novel therapeutic class (SoHO, Substances of Human Origin) in #HSCT and #GVHD. @Mohty_EBMT @TheEBMT nature.com/articles/s4140…

CONGRESS | #ASH25 | POSTER Everett Meyer presents data from a subgroup analysis of the phase III Precision-T trial of Orca-T versus tacrolimus + methotrexate (Tac/MTX) in patients with acute leukemia (N = 182). At 1 year, Orca-T demonstrated improved rates of chronic GvHD-free survival (78% vs 38%; p < 0.0001), OS (94% vs 83%; p = 0.045), GRFS (63% vs 31%; p < 0.0001), and NRM (13% vs 3.4%; p = 0.037) compared to Tac/MTX. Orca-T vs Tac/MTX showed improved clinical outcomes across patient subgroups with varied demographic and clinical features, including age, sex, donor type, and conditioning regimen. Follow our live feed for more updates: loom.ly/MbPzIiA Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #GvHD #GvHDsm #MedicalCongress @StanfordMed

Inviting all HCPs involved in care for stem cell transplant patients to our 1st KHP Preceptorship Event (3/4th Sept 2025) for Transplant complications with #GVHD This is a limited space event, so book early.. Registration/program details below.. eventbrite.co.uk/e/graft-versus…

AML at @EHA_Hematology 2025: Inqovi, Ziftomenib, Bleximenib, and More. Key updates on ORR, CR/CRi rates, and tolerability. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #AML #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @Dr_AmerZeidan | @AlkaliDr | @LeukDocJZ | @calliecoombsmd | @hemedoc | @AaronGoodman33 | @TalhaBadarMD | @SuyogCancer

Original Article: Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin (ALLG BM12 CAST phase 3 trial) nej.md/3Zpri7z #EHA2025 | @EHA_Hematology

Menin inhibitor studies at @EHA_Hematology 2025 in acute leukemia, focusing on NPM1-mutated and KMT2A-rearranged subsets. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #Hematology #Leukemia #CancerResearch #Oncology #CancerData #OncologyInsights | @Dr_AmerZeidan | @TalhaBadarMD | @smbenlazar | @hemedoc | @LeukDocJZ | @Abdallah81MD | @SuyogCancer

a comprehensive report of the survival outcomes among 240 patients who underwent a transplant at the MD Anderson Cancer Center for acute myeloid leukemia AML or myelodysplastic syndrome with TP53 mutations over a 10-year period. ow.ly/Y03x50W7qaE #transplantation

5. Key problem is inequity of access with some regions in UK undertaking markedly less activity. Need more awareness.

3. First report confirming more immunosuppression i.e. higher ATG doses do not confer additional benefit. Harmonised dosing essential! 4. Transplant related Mortality risk <1.5%, mainly seen with advanced disability and needs better optimisation/ careful selection essential

Hot off the press! Our UK wide 20years experience of Autologous #HSCT in #MultipleSclerosis reaffirming its significant benefits even with advanced disability @BSBMT @BritSocHaem @BrJHaem @TheEBMT @KingsCollegeNHS @mssocietyuk @MSTrust Key findings👇🏻 doi.org/10.1111/bjh.20…

Finally out.. 3rd edition of #COVID guidance by ECIL-10👇🏻🙏 Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy @TheEBMT @BritSocHaem @BSBMT @CDCgov @EHA_Hematology nature.com/articles/s4137…

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) nature.com/articles/s4137…

Real world study now out from our London MS HSCT group showing superior Effectiveness of Autologous #HSCT versus Alemtuzumab and Ocrelizumab in Relapsing #MultipleSclerosis @BSBMT @TheEBMT @KingsCollegeNHS @imperialcollege @TheNewANA1 onlinelibrary.wiley.com/doi/10.1002/an…

Take home messages on cGvHD #EBMT25 @Mohty_EBMT Best Belumosudil response takes time! >6mo to achieve it in some cases Most important… Great Impact on QoL! Very well tolerated treatment Good safety profile Great responses in heavily pretreated patients @TheEBMT

Long term data on FCC allografts in AA/BMF from @KingsCollegeNHS presented @TheEBMT 2025 showing excellent sustained outcomes over the years in both older and younger patients. Well done @Shreyas_H for presenting the data. More to come..@AustinKulasekar @vicpotter123

👉🏼@TheEBMT Prediction of outcomes post allo-HCT in Myelofibrosis via ML. Practical online tool to aid the transplant decision and discussion #MPNsm #EBMT25 hematology.org/newsroom/press… @TheEBMT @MosqueraOrgeira @AnnaSureda5 @TheEBMT_Trainee

Excellent conclusion of Mycology 2025 @FungalUpdate, discussing gains made so far and future challenges. Ended the day with sombre thoughts for the critical infectious disease programs in low income regions, where funding is severely cut, but we need to persevere @WHO.

Fascinating results of the 1st published study of HMA/Ven vs. 7+3 for younger AML pts in @BloodJournal. We cannot continue to Tx AML as a 1-size fits all paradigm. Intensive chemo still optimal for favorable-risk. But HMA/Ven may be best in select subgroups even in younger pts 👇